The US Food and Drug Administration’s global pilot program to promote regulatory convergence for gene therapies is only just beginning, but the agency already is eyeing a future expansion of its reach to earlier in the product development lifecycle.
The Collaboration on Gene Therapies (CoGenT) Global Pilot is an initiative to explore the potential for concurrent submission and collaborative...